Invivyd Reports Q3 2026 Revenue of $15.4 Million and $33.5 Million Net Loss

Invivyd reported Q3 2026 revenue of $15.4M, up from $13.1M a year earlier, and a net loss of $33.5M. Cash reserves stood at $126.4M. The company expects interim data from its DECLARATION Phase 3 trial soon and announced positive results from the LIBERTY Phase 3 trial.

Original reporting
Published Nov 16, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Invivyd Reports Q3 2026 Revenue of $15.4 Million and $33.5 Million Net Loss — source image
Decision brief

The 30-second read

$IVVDBearishHigh
01

Why it matters

The earnings release combines a financial miss with encouraging clinical data, creating a nuanced trade signal.

02

Market read

Primary earnings disclosure for a micro‑cap biotech with material trial data; relevant for short‑term traders and sector analysts.

03

What to watch

Potential regulatory delays for accelerated approval and competition from mRNA vaccine makers.

Relevance 8/10Novelty 8/10Timing: post-market filing

Background

Invivyd is a clinical‑stage biotech developing monoclonal antibodies for COVID‑19 and other viral diseases.

Company-level read

Ticker impact

$IVVDBearishHigh confidence
Context

Invivyd filed its Q3 2026 earnings showing revenue of $15.4M, a widened net loss of $33.5M, and positive Phase 3 interim data for VYD2311.

Expected impact

modest upside potential from trial data, offset by pressure from expanding loss

Evidence & confidence

The company reported a significant loss, which typically depresses price, but disclosed encouraging Phase 3 results that may attract investors seeking biotech upside.

Market effects

Positive trial data may lift peer biotech stocks focused on COVID‑19 therapeutics.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The widening loss suggests cash burn may outpace growth, making the stock overvalued despite trial optimism.

Key entities

  • Invivyd, Inc.

    Biotech firm reporting Q3 2026 results and trial updates.

  • Marc Elia

    Newly appointed CEO of Invivyd.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.